CD274 and esophageal squamous cell carcinoma: When the prices of serplulimab were decreased by 66%, 69% and 61%, respectively, serplulimab plus chemotherapy would be cost-effective in advanced ESCC patients with PD-L1-positive, PD-L1 1 ≤ CPS < 10 and CPS ≥ 10.